BPC-157 is a fifteen amino acid synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, derived from a protein sequence identified in human gastric juice. It has accumulated one of the most extensive bodies of preclinical research literature of any synthetic peptide, with studies spanning gastrointestinal biology, angiogenesis, tissue repair signaling, and central nervous system research.
Gastrointestinal and Mucosal Biology Research
Preclinical studies in rodent models have examined BPC-157's interactions with mucosal tissue, nitric oxide synthesis pathways, and inflammatory signaling in gut tissue. Research published in Current Pharmaceutical Design has documented extensive preclinical investigation into its interactions with gastrointestinal mucosal integrity mechanisms.
Angiogenesis and Vascular Research
BPC-157 has been studied extensively in the context of angiogenesis in preclinical models. Research has examined its interactions with VEGF signaling and its influence on endothelial cell behavior and cellular migration in experimental settings.
Tissue Repair Signaling
Preclinical studies have examined BPC-157's influence on fibroblast activity, cellular migration mechanisms, and growth factor receptor expression. Research has explored its interactions with EGR-1 transcription factor and FAK signaling pathways in experimental models.
Central Nervous System Research
Studies have investigated BPC-157's interactions with dopaminergic and serotonergic systems in rodent models, as well as its effects on GABA receptor expression and neuroprotective signaling in experimental settings.
• Sikiric P et al. (2018). Stable Gastric Pentadecapeptide BPC 157. Current Pharmaceutical Design, 24(18), 2002–2030.
• Chang CH et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing. Journal of Applied Physiology, 110(3), 774–780.
